Royal Bank of Canada
GNOM icon

Royal Bank of Canada’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Royal Bank of Canada’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111K Buy
1,955
+247
+14% +$11.8K ﹤0.01% 5336
2026
Q1 		$75K Sell
1,708
-66
-4% -$3.05K ﹤0.01% 5284
2025
Q4 		$81K Sell
1,774
-91
-5% -$4.03K ﹤0.01% 5310
2025
Q3 		$73K Buy
1,865
+307
+20% +$11.1K ﹤0.01% 5661
2025
Q2 		$53K Sell
1,558
-2,029
-57% -$64.2K ﹤0.01% 5895
2025
Q1 		$114K Buy
3,587
+29
+0.8% +$1.1K ﹤0.01% 5130
2024
Q4 		$139K Buy
3,558
+159
+5% +$6.68K ﹤0.01% 5111
2024
Q3 		$153K Sell
3,399
-1,349
-28% -$60.3K ﹤0.01% 5024
2024
Q2 		$199K Sell
4,748
-6,317
-57% -$264K ﹤0.01% 4775
2024
Q1 		$504K Buy
11,065
+7,664
+225% +$349K ﹤0.01% 3967
2023
Q4 		$157K Buy
3,401
+852
+33% +$34.7K ﹤0.01% 5286
2023
Q3 		$103K Sell
2,549
-632
-20% -$28.8K ﹤0.01% 5365
2023
Q2 		$154K Buy
3,181
+982
+45% +$49.1K ﹤0.01% 4973
2023
Q1 		$108K Sell
2,199
-81
-4% -$4.17K ﹤0.01% 5122
2022
Q4 		$115K Sell
2,280
-44,658
-95% -$2.3M ﹤0.01% 5339
2022
Q3 		$2.36M Buy
46,938
+39,346
+518% +$2.22M ﹤0.01% 2708
2022
Q2 		$371K Buy
7,592
+2,853
+60% +$145K ﹤0.01% 4322
2022
Q1 		$285K Buy
4,739
+1,323
+39% +$83.4K ﹤0.01% 4764
2021
Q4 		$271K Buy
3,416
+359
+12% +$30.2K ﹤0.01% 5038
2021
Q3 		$271K Sell
3,057
-790
-21% -$74K ﹤0.01% 4888
2021
Q2 		$383K Buy
3,847
+954
+33% +$84.6K ﹤0.01% 4500
2021
Q1 		$260K Buy
2,893
+153
+6% +$15.1K ﹤0.01% 4733
2020
Q4 		$259K Sell
2,740
-198
-7% -$16.6K ﹤0.01% 4669
2020
Q3 		$212K Buy
2,938
+824
+39% +$59K ﹤0.01% 4509
2020
Q2 		$148K Sell
2,114
-222
-10% -$13.8K ﹤0.01% 4619
2020
Q1 		$116K Buy
2,336
+8
+0.3% +$463 ﹤0.01% 4687
2019
Q4 		$145K Buy
2,328
+20
+0.9% +$1.15K ﹤0.01% 4849
2019
Q3 		$115K Buy
+2,308
New +$130K ﹤0.01% 4733

Other funds holding GNOM

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
FIA
Foundations Investment Advisors Phoenix, Arizona $9.72B AUM 29.41% 1-Year Est. Return

Royal Bank of Canada's GNOM Position: Q2 2026 in Review

Royal Bank of Canada increased its Global X Genomics & Biotechnology ETF (GNOM) stake by 14% in Q2 2026, buying an estimated $11.8K and bringing the position to 1,955 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #5336.

Royal Bank of Canada first reported a position in GNOM in Q3 2019 and has held it in 28 quarters since. The position peaked at $2.36M in Q3 2022. 48 funds tracked by Wall St. Rank hold GNOM as of Q2 2026.

  • Royal Bank of Canada held 1,955 shares of Global X Genomics & Biotechnology ETF worth $111K as of Q2 2026.
  • Royal Bank of Canada bought 247 Global X Genomics & Biotechnology ETF shares in Q2 2026, an estimated $11.8K.
  • Global X Genomics & Biotechnology ETF made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #5336 holding.
  • Royal Bank of Canada first reported a position in Global X Genomics & Biotechnology ETF in Q3 2019 and has held it in 28 quarters since.
  • Royal Bank of Canada's Global X Genomics & Biotechnology ETF position peaked at $2.36M in Q3 2022.
  • 48 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.